Rtw Investments Reduces $16M in Taysha Gene Therapies, Inc. ($TSHA)
RTW Investments cut its position in TSHA, selling 2.72 million shares.
Key Points
- RTW Investments reduced its stake in TSHA by 16.6%, selling 2,718,049 shares to hold 13,680,248 shares worth $78.1 million.
- TSHA shares are trading at $5.71 with a market cap of $78.1 million, lacking a meaningful P/E ratio due to unprofitability.
- Recent insider buys include John Stalfort III and Alison Long, while analysts maintain a 'buy' rating with price targets up to $17.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
RTW Investments has reduced its position in TSHA, according to its latest 13F filing with the SEC. The fund sold 2,718,049 shares, trimming its stake by 16.6% to 13,680,248 shares. As of the filing, these holdings were valued at approximately $78.1 million.
What Changed in RTW Investments' TSHA Position
RTW Investments cut its stake in TSHA from 16,398,297 shares to 13,680,248 shares, a decrease of 2,718,049 shares or 16.6%. The current value of its holdings is about $78.1 million.
Other Institutional Activity in TSHA
Several other funds also made moves in TSHA. RA Capital Management maintained its position with 23,555,648 shares valued at $105.3 million. Goldman Sachs Group significantly increased its holdings by 8,676,906 shares to a total of 22,369,645 shares, worth about $99.9 million. Avoro Capital Advisors held steady with 21,700,000 shares valued at $97 million. Meanwhile, BlackRock trimmed its position by 277,521 shares, ending with 18,365,608 shares worth $82.1 million. Vestal Point Capital boosted its stake by 4,250,000 shares, reaching 18,000,000 shares valued at $80.5 million.
Taysha Gene Therapies, Inc. Stock Down 1.0%
Shares of TSHA are trading at $5.71. The company has a market capitalization of approximately $78.1 million. TSHA lacks a meaningful P/E ratio as it is not currently profitable. The stock's 52-week range is not provided, but it is trading below its recent highs.
$TSHA stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Taysha Gene Therapies, Inc.
On June 1, 2026, several insiders made purchases in TSHA. John Stalfort III, Alison Long, and Laura Sepp-Lorenzo each bought 42,671 shares, while Laura Sepp-Lorenzo and John Stalfort III also purchased an additional 21,335 shares each. Phillip Donenberg acquired 21,335 shares as well. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
Analysts remain optimistic about TSHA. On April 6, 2026, Canaccord Genuity maintained a 'buy' rating with a price target of $17. Needham reiterated its 'buy' rating with a $12 target on March 20, while Chardan Capital also maintained a 'buy' with the same target on March 19. Overall, the consensus remains positive, with a mean target price reflecting strong potential upside.
About TSHA
TSHA operates in the biotechnology sector, focusing on developing gene therapies for the treatment of central nervous system disorders. The company is based in the United States and is engaged in research and development to address unmet medical needs in neurological conditions.
Bottom Line
RTW Investments' recent reduction in its TSHA holdings is part of a broader trend among institutional investors. These 13F filings are backward-looking and may not reflect current positions. Investors watch such movements for insights into fund strategies and market sentiment.
Get Taysha Gene Therapies, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TSHA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.